About 13,645 results

ALLMedicine™ Adenovirus Center

Research & Reviews  5,081 results

Novel group C oncolytic adenoviruses carrying a microRNA inhibitor demonstrate enhanced...
Molecular Cancer Therapeutics; Doerner J, Sallard E et. al.

Jan 15th, 2022 - Oncolytic adenoviruses (OAds) represent an attractive treatment option for cancer. Clinical efficacy of commonly utilized human Ad type 5 (Ad5) based oncolytic viruses is limited by variable expression levels of the coxsackie- and adenovirus recep...

M11: A Tropism-modified Oncolytic Adenovirus Arming with Tumor-homing Peptide for Advan...
Human Gene Therapy; Gao Q, Li F et. al.

Jan 13th, 2022 - Oncolytic adenoviruses (OAds) have shown great promise in cancer therapy, but their efficacy has been greatly limited by poor tumor selectivity and highly off-target liver sequestration. Herein, we generate a novel "stealth' and tumor-targeting on...

Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral vi...
Journal for Immunotherapy of Cancer; Koch MS, Zdioruk M et. al.

Jan 13th, 2022 - Intratumoral viral oncolytic immunotherapy is a promising new approach for the treatment of a variety of solid cancers. CAN-2409 is a replication-deficient adenovirus that delivers herpes simplex virus thymidine kinase to cancer cells, resulting i...

see more →

Guidelines  1 results

Community acquired respiratory virus infections in cancer patients-Guideline on diagnos...
European Journal of Cancer (Oxford, England : 1990); von Lilienfeld-Toal M, Berger A et. al.

Sep 30th, 2016 - Community acquired viruses (CRVs) may cause severe disease in cancer patients. Thus, efforts should be made to diagnose CRV rapidly and manage CRV infections accordingly. A panel of 18 clinicians from the Infectious Diseases Working Party of the G...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  127 results

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Jan 12th, 2022 - To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55, inclusive, and to assess the safety and tolerability of VXA- G1.1-...

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Jan 5th, 2022 - During the period of immune recovery after allogeneic hematopoietic cell transplant (allo-HCT), viral infections and reactivations, including those with AdV, are an important cause of morbidity and mortality. Progression to AdV disease is associat...

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Dec 22nd, 2021 - The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactu...

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

Dec 20th, 2021 - This is a prospective, single blinded randomised clinical study, designed to provide data on the heterologous prime boost use of AZD1222 and rAd26-S, to be administered one after the other interchangeably. This study aims to explore the immunogeni...

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]

Dec 2nd, 2021 - ICOVID-19 vaccination programs worldwide have so far focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore two mRNA vaccines developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), have been gran...

see more →

News  233 results

Why mRNA COVID vaccines are preferred (and why patients should be reassured)
Doug Campos-Outcalt, MD, MPA

Jan 3rd, 2022 - On December 16, 2021, the Advisory Committee on Immunization Practices (ACIP) voted to preferentially recommend messenger RNA (mRNA) vaccines over the Johnson & Johnson/Janssen (J&J) COVID-19 (Ad. 26.

CDC Staff: One mRNA Dose Better Than J&J, Even Among Elusive Patients

Dec 17th, 2021 - Clinicians should not automatically give the Johnson & Johnson COVID-19 vaccine even if they suspect patients will not return for a second dose of mRNA vaccine, CDC staff said on a call with clinicians on Friday. CDC's Advisory Committee on Immuni...

CDC Panel Backs mRNA COVID Vaccines Over J&J Due to Rare Clot Risk

Dec 16th, 2021 -  Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A panel of vaccine experts that advises the Centers for Disease Control and Prevention (CDC) on the use of vaccines in the United States said the...

Small Myocarditis Risk Now Seen for Adenovirus-based COVID-19 Vaccine

Dec 16th, 2021 - The first large population study to investigate the association between different COVID-19 vaccines types and cardiac effects and adverse events shows a small increase in the risk for acute myocarditis with both the mRNA-based vaccines and — in wh...

FDA Updates Risks, Cautions for Clotting-Bleeding Disorder on Janssen COVID-19 Vaccine

Dec 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Updated Janssen/Johnson & Johnson COVID-19 vaccine fact sheets for healthcare professionals and the general public now include a contraindication ...

see more →

Patient Education  4 results see all →